查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
移植骨替代物市场：2023 年至 2028 年预测
市场调查报告书
商品编码
1410016

移植骨替代物市场：2023 年至 2028 年预测

Bone Graft Substitute Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

移植骨替代物市场预计在预测期内复合年增长率为 6.43%。

移植骨替代物用于预防疾病感染和供体部位併发症并减少手术时间。人口中不断增加的骨骼疾病和整形外科手术是移植骨替代物市场的主要成长要素。此外，由于植入手术数量的增加，牙科产业的需求不断增加，预计也将在未来几年推动移植骨替代物市场。此外，技术进步和政府产品核准导致合成骨移植的可及性提高，预计将进一步推动移植骨替代物市场。

骨骼疾病增加

有多种健康状况与骨骼密度和矿物质有关，包括骨质疏鬆症、骨质缺乏症、佩吉特氏症、成骨不全症和骨关节炎，这些疾病特别会导致肌肉骨骼问题。此类骨相关疾病病例的不断增加增加了对移植骨替代物的需求，以改善或取代自体骨移植。据世界卫生组织称，到 2022 年，全球将有约 1.71 人患有肌肉骨骼问题，成为残疾的主要原因。此外，肌肉骨骼问题是导致残疾寿命 (YLD) 的最大因素，占全球整体残疾寿命的 17%。如果不及时治疗，骨骼疾病可能会导致严重的健康问题，影响您的身体、心理和情绪健康。随着病例的增加，这种负面影响预计将推动移植骨替代物市场的发展。

整形外科手术增加

骨骼疾病和骨质疏鬆症的增加导致整形外科手术的增加，推动了移植骨替代物市场。例如，德国Gelenk Klinik医院每年收治超过24,000名整形外科患者，其中涉及外科手术的病例超过2,400例。 Business Standard 估计美国每年约进行 200 万例关节重建。

人工植牙需求增加

由于人工植牙手术数量的增加以及患者对微创手术的偏好，牙科领域对移植骨替代物的需求正在增加。市面上有多种移植骨替代物，包括同种异体移植物、自体移植物、异种移植物、鼻窦增高术和上颚窦提升术。据美国植牙牙科学会称，每年约有 1500 万美国人用牙桥或牙冠替换缺失的牙齿。此外，《植牙官方杂誌》报道称，在近 40% 的植入病例中，没有足够的骨质使植入正确整合，需要进行骨移植。

人口老化

在高龄化社会中，骨骼密度趋于下降，这是许多骨骼疾病和手术的原因。全球人口老化的加剧显示未来几年对移植骨替代物的需求。例如，根据世界卫生组织估计，60岁及以上人口预计将从2020年的10亿增加到2030年的14亿，2050年将达到21亿人。随着年龄的增长，我们的骨骼变得越来越脆，更容易骨折，因此骨质疏鬆症患者的数量也在增加。根据骨与关节负担组织的数据，65 岁以上的人中有近四分之三患有肌肉骨骼疾病，这表明移植骨替代物市场正在不断增长。

市场机会

整形外科和骨骼疾病数量的不断增加以及对微创外科手术的需求正在推动移植骨替代物市场的发展，为新进入者提供了巨大的机会。此外，有利的政府法规和对移植骨替代物的核准进一步扩大了扩张机会。 2021年，FDA核准了24种移植骨替代物，包括PMMA骨水泥、生物活性玻璃、硫酸钙、磷酸钙水泥和双相磷酸钙。此外，改善各种牙科、脊椎和整形外科植入的患者体验和舒适度的技术进步也有望扩大移植骨替代物的市场规模并带来更多机会。

预计北美在预测期内将大幅成长

预计在预测期内，北美地区将占据移植骨替代物市场的重要份额。造成这一巨大份额的因素包括该地区大量骨质疏鬆患者、政府核准和技术进步。例如，根据骨骼健康和骨质疏鬆症基金会的数据，目前约有 5,400 万美国人患有骨质疏鬆症。此外，在美国，骨质疏鬆症每年导致约 200 万例骨折，预计每两名女性中就有一人会在 50 岁时因骨质疏鬆症而发生骨折。此外，Arthrex、强生公司和史赛克公司等市场领先公司在该地区的存在预计也将透过改善准入和产品进步来推动移植骨替代物市场的发展。

主要进展

2023年5月，Royal Biologics推出Bio-Reign 3D移植骨替代物。降解曲线允许骨形成并随着骨癒合而变得渗透性。 2022年3月，Molecular Matrix宣布合成移植骨替代物Osteo-P®全面商业化。使用超级交联碳水化合物聚合物（HCCP）技术修復和再生骨骼。 2020年6月，Bioventus推出了新型带状移植骨替代物SIGNAFUSE。骨移植的矿物结构由60%羟磷石灰和40%β-磷酸三钙组成。

公司产品

总部位于美国的 Arthrex 专注于整形外科，帮助外科医生更好地治疗患者。该公司的 OSferion 是一种骨传导移植骨替代物，由 100% β-磷酸三钙製成。强生公司是一家多专业医疗保健公司，自 20 世纪 40 年代以来一直提供服务。 2023 年 5 月，该公司获得 FDA 批准，可以在反向肩关节置换术中使用 INHANCE(TM) 肩关节系统。该公司提供使用 β-磷酸三钙的合成 Kronos®移植骨替代物(CMF)，有颗粒和预成型件形式。美敦力公司是一家领先的医疗技术公司，提供先进的外科技术解决方案。公司提供的植骨材料包括Grafton（TM）DBF注射液、Infuse（TM）植骨材料、Manifuse（TM）植骨材料、Master Graft（TM）系列，用于微创手术和开放性手术。你可以

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章移植骨替代物市场：依类型

  • 介绍
  • 同种异体移植物
  • 骨移植置换
  • 基于细胞的矩阵

第六章移植骨替代物市场：依应用分类

  • 介绍
  • 脊椎融合手术
  • 创伤
  • 关节重组
  • 牙科骨移植
  • 颅颚颜面

第七章移植骨替代物市场：依最终用户分类

  • 介绍
  • 医院
  • 专科诊所
  • 其他的

第八章移植骨替代物市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 伊斯拉尔
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Arthrex, Inc.
  • Johnson & Johnson
  • Medtronic plc
  • Stryker Corporation
  • Baxter International Inc.
  • Xtant Medical Holdings, Inc.
  • Integra LifeSciences
  • NuVasive, Inc.
  • Zimmer Biomet Holdings, Inc.
  • Orthofix Holdings, Inc
简介目录
Product Code: KSI061615655

The bone graft substitute market is expected to grow at a CAGR of 6.43% during the forecast period.

Bone graft substitutes are used to prevent disease transmission and donor-site complications and reduce operative time. The rising bone diseases and orthopedic surgeries among the population are major growth factors in the bone graft substitute market. Moreover, the increasing demand from the dental sector due to the rising number of implant procedures is also expected to propel the bone graft substitute market in the coming years. Additionally, the technological advancements leading to enhanced synthetic bone graft accessibility coupled with approval of products by the government are further contemplated to boost the bone graft substitute market.

Growing Prevalence of Bone Diseases

There is various health condition related to bone density and minerals such as osteoporosis, osteopenia, Paget's disease, osteogenesis imperfecta, and osteoarthritis, among others creating a musculoskeletal problem. The growing cases of these bone-related diseases are pushing the demand for bone graft substitutes to improve or replace autogenous bone grafts. According to WHO, around 1.71 people had musculoskeletal problems worldwide in 2022 and it is the leading cause of disability. Moreover, musculoskeletal problems are the biggest contributor to years lived with disability (YLD) accounting for 17% of total YLDs globally. Bone disease causes serious health problems affecting physical, mental, and emotional health if not treated on time. The adverse effect along with the rising cases is anticipated to propel the bone graft substitute market.

Rising Orthopedic Surgeries

The rising number of bone diseases and osteoporosis is leading to more orthopedic surgeries and thereby propelling the bone graft substitute market. For instance, Gelenk Klinik Hospital of Germany treats more than 24,000 orthopaedic patients per year with more than 2400 cases involving surgical procedures. Around 2 million joint replacement surgeries happen in the US every year as per the estimates of Business Standard.

Increasing Demand for Dental Implants

The demand for bone graft substitutes in dentistry is rising owing to the growing number of dental implant procedures and patients' preference for minimally invasive procedures. There are several bone graft substitutes available in the market including allograft, autograft, xenograft, alloplastic, and sinus lift. According to the American Academy for Implant Dentistry, approximately 15 million Americans replace missing teeth with bridges and crowns each year, which increases the need for dental implants thereby propelling the bone graft substitutes market. Moreover, in almost 40% of all implant cases, there is insufficient bone to achieve good implant integration, necessitating the use of bone graft replacements as per the Implant Dentistry Official Journal.

Aging Population

Ageing populations are more prone to low bone density leading to numerous bone diseases and surgery. The growing number of ageing people worldwide indicates the need for bone graft substitutes in the coming years. For instance, the number of people aged 60 or above will increase to 1.4 billion by 2030 from 1 billion in 2020 and it is projected to reach 2.1 billion by 2050 as per the WHO estimates. In old age, bones become brittle and there is a higher chance of breaking leading to more cases of osteoporosis in this age group. According to the Bone and Joint Burden Organization, nearly 3 out of 4 people aged 65 or above suffer from musculoskeletal disease indicating the bone graft substitute market expansion.

Opportunities in the Market

The rising orthopedic and bone diseases coupled with the demand for minimally invasive surgical procedures are propelling the bone graft substitute market thereby providing a phenomenal opportunity for new entrants. Moreover, the favorable government regulations and approvals of bone graft substitutes further extend an expansion opportunity. In 2021, there were 24 types of bone graft substitutes approved by the FDA including PMMA Bone Cement, Bioactive Glass, Calcium Sulfate, Calcium Phosphate Cement, and Biphasic Calcium Phosphate among others. Furthermore, the technological advancements to enhance patient experience and comfort in diversified implantation for dental, spinal, and orthopedic are also expected to boost the bone graft substitute market size leading to increased opportunity.

North America is expected to grow considerably during the forecast period

North American region is expected to hold a significant share of the bone graft substitute market during the forecasted period. Various factors attributed to such a significant share are a huge number of osteoporosis cases, government approvals, and technological advancements in the region. For instance, approximately 54 million Americans have osteoporosis currently as per the Bone Health and Osteoporosis Foundation. Moreover, osteoporosis causes around two million broken bones every year in America and one in two women are expected to have a bone fracture by the age of 50 due to osteoporosis. Further, the presence of some of the market leaders such as Arthrex, Johnson & Johnson, and Stryker Corporation in the region is also expected to boost the bone graft substitute market through increasing accessibility and product advancements.

Key Developments

  • In May 2023, Bio-Reign 3D bone graft substitute was launched by the Royal Biologics which is made with a natural hyper-crosslinked carbohydrate polymer. It enables bone formation with its degradation profile, and it becomes radiopaque as the bone heals.
  • In March 2022, the full commercial launch of the Osteo-P® synthetic bone graft substitute was announced by Molecular Matrix. The hyper-crosslinked carbohydrate polymer (HCCP) technology was used to create it to repair and regenerate bone.
  • In June 2020, a new bone graft substitute SIGNAFUSE was launched by Bioventus in a new strip format. The mineral structure of the bone graft was made with 60% hydroxyapatite and 40% beta-tricalcium phosphate.

Company Products

  • Arthrex, a US-based company focuses on orthopaedics to help surgeons better treat their patients. The company offers OSferion which is an osteoconductive bone graft substitute made from 100% beta-tricalcium phosphate.
  • Johnson & Johnson, it is a multi-specialty healthcare company offering services since the 1940s. In May 2023, the company got clearance from the FDA to use its INHANCE™ shoulder system in reverse shoulder replacement surgeries. The company offers synthetic chronOS® Bone Graft Substitute (CMF) made with beta-tricalcium phosphate and it is available as granules and preformed shapes.
  • Medtronic Plc, they are one of the leading medical technology companies which provide advanced surgical technology solutions. The bone grafting substitute offered by the company is Grafton™ DBF inject, Infuse™ Bone Graft, Magnifuse™ Bone Graft, and Mastergraft™ Family for minimally invasive and open procedures.

Segmentation:

By Type

  • Allografts
  • Bone grafts Substitutes
  • Cell-based Matrices

By Application

  • Spinal Fusion
  • Trauma
  • Joint Reconstruction
  • Dental Bone Grafting
  • Craniomaxillofacial

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. BONE GRAFT SUBSTITUTE MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Allografts
  • 5.3. Bone grafts Substitutes
  • 5.4. Cell-based Matrices

6. BONE GRAFT SUBSTITUTE MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Spinal Fusion
  • 6.3. Trauma
  • 6.4. Joint Reconstruction
  • 6.5. Dental Bone Grafting
  • 6.6. Craniomaxillofacial

7. BONE GRAFT SUBSTITUTE MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Specialty Clinics
  • 7.4. Others

8. BONE GRAFT SUBSTITUTE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Isral
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Arthrex, Inc.
  • 10.2. Johnson & Johnson
  • 10.3. Medtronic plc
  • 10.4. Stryker Corporation
  • 10.5. Baxter International Inc.
  • 10.6. Xtant Medical Holdings, Inc.
  • 10.7. Integra LifeSciences
  • 10.8. NuVasive, Inc.
  • 10.9. Zimmer Biomet Holdings, Inc.
  • 10.10. Orthofix Holdings, Inc